Aprogen Medicines Inc.
Records under this name other than patents Aprogen Medicines Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Aprogen Medicines Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,259,860 | Fusion Proteins Binding to VEGF and Angiopoietin Formerly held In force · High confidence | In force | High confidence | |
| US 10,246,517 | Antibody Binding to Carbonic Anhydrase and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,676,531 | Anti-CD43 antibody and use thereof for cancer treatment Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,975,160 | Antibody binding to carbonic anhydrase and use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,542,339 | Anti-CD43 antibody and use thereof for cancer treatment Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,820,831 | Antibody Binding to Carbonic Anhydrase and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,192,959 | Antibody Binding to Carbonic Anhydrase and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 7,691,366 | Chimeric CMP-Ang1 molecule Formerly held Term ended Term ended Oct 18, 2022 · USPTO record | Term ended | Term ended Oct 18, 2022 | USPTO record |